JP2012517965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517965A5 JP2012517965A5 JP2011549472A JP2011549472A JP2012517965A5 JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5 JP 2011549472 A JP2011549472 A JP 2011549472A JP 2011549472 A JP2011549472 A JP 2011549472A JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- reaction
- above meanings
- compound
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09152805.9 | 2009-02-13 | ||
| EP09152805 | 2009-02-13 | ||
| PCT/EP2010/000717 WO2010091824A1 (en) | 2009-02-13 | 2010-02-05 | Fused pyrimidines as akt inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517965A JP2012517965A (ja) | 2012-08-09 |
| JP2012517965A5 true JP2012517965A5 (enExample) | 2014-09-04 |
| JP5667085B2 JP5667085B2 (ja) | 2015-02-12 |
Family
ID=42019301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549472A Expired - Fee Related JP5667085B2 (ja) | 2009-02-13 | 2010-02-05 | Ａｋｔインヒビターとしての融合されたピリミジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130310362A1 (enExample) |
| EP (1) | EP2396331B1 (enExample) |
| JP (1) | JP5667085B2 (enExample) |
| CN (1) | CN102361872B (enExample) |
| CA (1) | CA2752114C (enExample) |
| ES (1) | ES2435804T3 (enExample) |
| WO (1) | WO2010091824A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156831B2 (en) * | 2013-01-23 | 2015-10-13 | Astrazeneca Ab | Chemical compounds |
| CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0309398A (pt) * | 2002-04-19 | 2005-02-01 | Cellular Genomics Inc | Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase |
| AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| CA2561311A1 (en) | 2004-04-09 | 2005-10-27 | Merck & Co., Inc. | Inhibitors of akt activity |
| US7544677B2 (en) | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| EP1812439B2 (en) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2008524339A (ja) * | 2004-12-15 | 2008-07-10 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性のインヒビター |
| AU2006216998B2 (en) | 2005-02-14 | 2010-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| WO2006135627A2 (en) | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| CA2695251C (en) * | 2007-08-14 | 2016-06-21 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| CA2694058C (en) * | 2007-08-14 | 2016-06-07 | Bayer Schering Pharma Aktiengesellschaft | Fused bicyclic pyrimidines |
-
2010
- 2010-02-05 US US13/201,227 patent/US20130310362A1/en not_active Abandoned
- 2010-02-05 WO PCT/EP2010/000717 patent/WO2010091824A1/en not_active Ceased
- 2010-02-05 ES ES10703022T patent/ES2435804T3/es active Active
- 2010-02-05 CN CN201080012970.3A patent/CN102361872B/zh not_active Expired - Fee Related
- 2010-02-05 CA CA2752114A patent/CA2752114C/en not_active Expired - Fee Related
- 2010-02-05 EP EP10703022.3A patent/EP2396331B1/en not_active Not-in-force
- 2010-02-05 JP JP2011549472A patent/JP5667085B2/ja not_active Expired - Fee Related